Anaptysbio
ANAB----
Anaptysbio (ANAB)
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United S...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Anaptysbio Analyst Rating
View MoreForecast & Rating
Jul 21, 2026Price forecast
$87.0960.83%
Forecast & RatingStrong buy
11analysts
- Strong buy72.73%
- Buy27.27%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Tip Ranks · Jul 21 at 02:23 PM
Buy Rating Reaffirmed on Litigation Clarity and Asset Value; $95 Price Target Maintained
- Tip Ranks · Jul 14 at 03:46 AM
Barclays Keeps Their Buy Rating on AnaptysBio (ANAB)
- Simplywall · Jul 6 at 11:06 AM
Is AnaptysBio (ANAB) Undervalued As Russell Index Deletions Reshape Trading Flows?
- Simplywall · Jun 30 at 10:51 AM
Is AnaptysBio’s (ANAB) Index Exit and Office Sublease Quietly Reframing Its Strategic Focus?
- PUBT · Jun 29 at 03:06 PM
AnaptysBio announces annual shareholder meeting
- PUBT · Jun 22 at 03:06 PM
AnaptysBio subleases 45,057 sq ft San Diego office space to First Tracks Biotherapeutics
